Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma

Combination of 5-Fluorouracil, Adriamycin, Ifosfamide and Cisplatin in Metastatic Adult Soft Tissue Sarcoma: Results of a Phase II Study

“…The objective response rate of 30% is clearly inferior to response rates reported from recent phase II studies with high dose ADM/IFO and comparable to the results of CYVADIC, standard-dose ADM/IFO or high-dose singleagent ADM [4,5,7,8,10,12,13,19], Hematological G-CSF was administered only in 8/35 patients with severe neutropenia. It was demonstrated that 7/8 patients could be referred to the next treatment cycle without toxicityrelated delay.…”

Combination of 5-Fluorouracil, Adriamycin, Ifosfamide and Cisplatin in Metastatic Adult Soft Tissue Sarcoma: Results of a Phase II Study

“…The objective response rate of 30% is clearly inferior to response rates reported from recent phase II studies with high dose ADM/IFO and comparable to the results of CYVADIC, standard-dose ADM/IFO or high-dose singleagent ADM [4,5,7,8,10,12,13,19], Hematological G-CSF was administered only in 8/35 patients with severe neutropenia. It was demonstrated that 7/8 patients could be referred to the next treatment cycle without toxicityrelated delay.…”

Chemotherapy of Soft Tissue Sarcoma

“…We used this combination also for advanced disease. A similar type of treatment has been reported to give an RR of 35 Á/45% in studies elsewhere (17,18). The same combination was also used in the study by Santoro et al (10), but with no significant clinical benefit over that derived from doxorubicin alone (RR 25.2% vs. 21.3%).…”

The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas

“…In 1990, the EORTC group embarked on a phase II trial of doxorubicin (50 mg/m 2 ) plus ifosfamide (5 g/m 2 ) administered as a 24-hour continuous infusion every 3 weeks. In that study, toxicity was shown to be acceptable, with a response rate of 35% in 175 assessable patients [66]. Several other studies combining doxorubicin with ifosfamide, all performed in a nonrandomized setting, demonstrated apparently high response rates of 50%-60%.…”

Combination of 5-Fluorouracil, Adriamycin, Ifosfamide and Cisplatin in Metastatic Adult Soft Tissue Sarcoma: Results of a Phase II Study

“…The objective response rate of 30% is clearly inferior to response rates reported from recent phase II studies with high dose ADM/IFO and comparable to the results of CYVADIC, standard-dose ADM/IFO or high-dose singleagent ADM [4,5,7,8,10,12,13,19], Hematological G-CSF was administered only in 8/35 patients with severe neutropenia. It was demonstrated that 7/8 patients could be referred to the next treatment cycle without toxicityrelated delay.…”

Chemotherapy of Soft Tissue Sarcoma

“…We used this combination also for advanced disease. A similar type of treatment has been reported to give an RR of 35 Á/45% in studies elsewhere (17,18). The same combination was also used in the study by Santoro et al (10), but with no significant clinical benefit over that derived from doxorubicin alone (RR 25.2% vs. 21.3%).…”

The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas

“…In 1990, the EORTC group embarked on a phase II trial of doxorubicin (50 mg/m 2 ) plus ifosfamide (5 g/m 2 ) administered as a 24-hour continuous infusion every 3 weeks. In that study, toxicity was shown to be acceptable, with a response rate of 35% in 175 assessable patients [66]. Several other studies combining doxorubicin with ifosfamide, all performed in a nonrandomized setting, demonstrated apparently high response rates of 50%-60%.…”

Combination of 5-Fluorouracil, Adriamycin, Ifosfamide and Cisplatin in Metastatic Adult Soft Tissue Sarcoma: Results of a Phase II Study

“…The objective response rate of 30% is clearly inferior to response rates reported from recent phase II studies with high dose ADM/IFO and comparable to the results of CYVADIC, standard-dose ADM/IFO or high-dose singleagent ADM [4,5,7,8,10,12,13,19], Hematological G-CSF was administered only in 8/35 patients with severe neutropenia. It was demonstrated that 7/8 patients could be referred to the next treatment cycle without toxicityrelated delay.…”

Chemotherapy of Soft Tissue Sarcoma

“…We used this combination also for advanced disease. A similar type of treatment has been reported to give an RR of 35 Á/45% in studies elsewhere (17,18). The same combination was also used in the study by Santoro et al (10), but with no significant clinical benefit over that derived from doxorubicin alone (RR 25.2% vs. 21.3%).…”

The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas

“…In 1990, the EORTC group embarked on a phase II trial of doxorubicin (50 mg/m 2 ) plus ifosfamide (5 g/m 2 ) administered as a 24-hour continuous infusion every 3 weeks. In that study, toxicity was shown to be acceptable, with a response rate of 35% in 175 assessable patients [66]. Several other studies combining doxorubicin with ifosfamide, all performed in a nonrandomized setting, demonstrated apparently high response rates of 50%-60%.…”